Companies in #Non-Muscle Invasive Bladder Cancer
Found 1 company operating in this sector.
CG Oncology is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy, for non-muscle invasive bladder cancer. Its Phase 3 program spans BOND-003 in BCG-unresponsive disease and PIVOT-006 as adjuvant monotherapy in intermediate-risk disease following TURBT, with earlier studies exploring high-risk and BCG-naïve populations.